Danielle Porter to Humans
This is a "connection" page, showing publications Danielle Porter has written about Humans.
Connection Strength
0.024
-
Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks. Antivir Ther. 2017; 22(6):495-502.
Score: 0.006
-
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. Cell Rep. 2021 07 27; 36(4):109450.
Score: 0.002
-
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Clin Pharmacokinet. 2021 05; 60(5):569-583.
Score: 0.002
-
Reply to Yan and Muller, "Remdesivir for COVID-19: Why Not Dose Higher?" Antimicrob Agents Chemother. 2021 03 18; 65(4).
Score: 0.002
-
Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir. Antiviral Res. 2021 04; 188:105033.
Score: 0.002
-
Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent. Antimicrob Agents Chemother. 2021 01 20; 65(2).
Score: 0.002
-
Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases. Proc Natl Acad Sci U S A. 2020 10 27; 117(43):26946-26954.
Score: 0.002
-
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 01 10; 11(1):222.
Score: 0.002
-
Characterisation of infectious Ebola virus from the ongoing outbreak to guide response activities in the Democratic Republic of the Congo: a phylogenetic and in vitro analysis. Lancet Infect Dis. 2019 09; 19(9):1023-1032.
Score: 0.002
-
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide. J Infect Dis. 2017 03 15; 215(6):920-927.
Score: 0.001
-
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017 05; 4(5):e205-e213.
Score: 0.001
-
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017 05; 4(5):e195-e204.
Score: 0.001